Clinical Trial Update: Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating venetoclax for relapsed hairy cell leukemia is currently recruiting, sponsored by the National Cancer Institute.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia

Drugs mentioned

• Venetoclax (venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant | Phase 2 | Status: RECRUITING